FTC and New York settle with Vyera ahead of trial

Ben Remaly

08 December 2021

Vyera Pharmaceuticals has agreed to pay up to $40 million to settle allegations that it illegally prevented generic competition for its infection treatment Daraprim.

Subscribe to Global Competition Review

Subscribe to unlock unlimited access

Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.

Subscribe now

Already have access? Login below

Ben Remaly

View full biography

Author | Editor, GCR USA

[email protected]

Tipline

Bridging troubled waters: The Tipline for 26 January 2023
Many mistakenly believe Pittsburgh has more bridges than any other city in the world, yet the “City of Bridges” does not even have the most in Pennsylvania. The largest union of journalists says another mistake is thinking that the city has a vibrant news market. NewsGuild-CWA is calling on the Department of Justice to take a close look at the Pittsburgh Post-Gazette’s plan to buy the Pittsburgh City Paper. Also in Tipline, Amazon fails …
Don’t blame me: The Tipline for 25 January 2023
Call to the Barr: The Tipline for 24 January 2023

FTC and New York settle with Vyera ahead of trial

Subscribe to Global Competition Review

Subscribe to unlock unlimited access

Already have access? Login below

Related Topics

Ben Remaly